Skip to Content

Glypican-3 Antibodies

Glypican-3 Antibodies

Gene Name: Glypican-3 (GPC3)

Function:

  • Glypican-3 is a cell surface heparan sulfate proteoglycan involved in various cellular processes, including cell growth, proliferation, and differentiation.
  • It interacts with signaling molecules and modulates pathways such as the Wnt/β-catenin pathway, contributing to cell signaling and tissue development.
  • Dysregulation of Glypican-3 expression or activity may influence tumor growth, metastasis, and angiogenesis in cancer.

Immune Regulation:

  • Glypican-3 expression on tumor cells may influence immune responses within the tumor microenvironment.
  • Tumors expressing Glypican-3 may exhibit immunosuppressive characteristics, such as increased expression of immune checkpoint molecules or recruitment of regulatory immune cell populations.
  • Targeting Glypican-3-positive tumor cells with immunotherapeutic approaches, such as vaccines or CAR-T cell therapies, aims to enhance anti-tumor immune responses and overcome immunosuppression.

Apoptosis:

  • While the direct role of Glypican-3 in apoptosis regulation is not fully understood, dysregulation of Glypican-3 expression or activity may impact apoptotic signaling pathways, contributing to cancer cell survival and tumor progression.

Research Implications:

  • Understanding the functions of Glypican-3 is essential for elucidating its roles in development, tissue homeostasis, and disease.
  • Research on Glypican-3 may have implications for various fields, including cancer biology, regenerative medicine, and immunotherapy.

Clinical Relevance:

  • Dysregulation of Glypican-3 expression is associated with various cancers, including hepatocellular carcinoma (HCC) and other malignancies.
  • Investigating Glypican-3's role as a diagnostic marker or therapeutic target may provide insights into disease mechanisms and treatment strategies.
  • Glypican-3-targeted therapies, such as monoclonal antibodies or antibody-drug conjugates, are being developed and evaluated in clinical trials for the treatment of Glypican-3-positive cancers. These therapies hold promise for improving patient outcomes and overcoming treatment resistance.
815.00 815.0 USD
AffiAB® Anti-Glypican-3 Antibody
CAT# AFG-BMG-3117
Size: 100 µg
210.50 210.5 USD
AffiAB® Anti Human GPC3 Polyclonal Antibody
CAT# AFG-BMG-1170
Size: 100 µl
742.85 742.85 USD
AffiAB® Glypican-3 Antibody
CAT# AFG-BMG-0186
Size: 0.1 mL
236.11 236.11 USD
AffiAB®​​ GPC39 Polyclonal Antibody
CAT# AFG-BTL-05509
Size: 100 uL
382.50 382.5 USD
AffiAB®​​ Glypican-3 Polyclonal Antibody
CAT# AFG-BTL-05434
Size: 100 uL
382.50 382.5 USD
AffiAB® Anti-Glypican-3 GPC3 Antibody
CAT# AFG-BRB-02772
Size: 100 μL
688.65 688.65 USD
815.00 815.0 USD
AffiAB® Rabbit anti-Glypican 3 Antibody
CAT# AFG-DDA-3229
Size: 100 μL
284.05 284.05 USD
AffiAB® GPC3 Polyclonal Antibody
CAT# AFG-PAB-05836
Size: 100 µg
Conjugation: Unconjugated
335.50 335.5 USD
AffiAB® Rabbit anti-Glypican 3 Antibody
CAT# AFG-YBP-3672
Size: 100 µL
457.00 457.0 USD
AffiAB® GPC3 Antibody
CAT# AFG-IVA-12379
Size: 100 µg
Terminal: N/A
719.15 719.15 USD
AffiAB® GPC39 Rabbit Polyclonal Antibody
CAT# AFG-EKA-11239
Size: 100 µL
246.00 246.0 USD
AffiAB® Glypican-3 Rabbit Polyclonal Antibody
CAT# AFG-EKA-03441
Size: 100 µL
246.00 246.0 USD